Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus

A. Vella, J. S. Lee, M. Camilleri, L. A. Szarka, D. D. Burton, A. R. Zinsmeister, R. A. Rizza, P. D. Klein

Research output: Contribution to journalArticlepeer-review

90 Scopus citations


Pramlintide delays gastric emptying, possibly by a centrally mediated mechanism. Our aim was to determine whether the effects of pramlintide on gastric emptying differ in people with type 1 or type 2 diabetes who had no history of complications. Using a randomized, three-period, two-dose, crossover design, we studied the effects of 0, 30, or 60 μg t.i.d. pramlintide subcutaneously for 5 days each in six type 1 and six type 2 diabetic subjects. Gastric emptying of solids was measured by 13C-Spirulina breath test. Plasma pancreatic polypeptide (HPP) response to the test meal was also measured. Relative to placebo [t 50% 91 ± 6 min (means ± SEM)], pramlintide equally delayed gastric emptying following 30 or 60 μg t.i.d. (268 ± 37 min, 329 ± 49 min, respectively; P < 0.01]. Postprandial HPP levels were lower in response to 30 and 60 μg pramlintide compared to placebo. There were no significant differences in the effects on gastric emptying or HPP levels between type 1 and type 2 diabetic subjects. Pramlintide delays gastric emptying in diabetes unassociated with clinically detected complications. Further studies are needed in diabetic patients with impaired gastric motor function.

Original languageEnglish (US)
Pages (from-to)123-131
Number of pages9
JournalNeurogastroenterology and Motility
Issue number2
StatePublished - 2002


  • Glucose
  • Pancreatic polypeptide

ASJC Scopus subject areas

  • Physiology
  • Endocrine and Autonomic Systems
  • Gastroenterology


Dive into the research topics of 'Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus'. Together they form a unique fingerprint.

Cite this